Integrated serum screening is available with or without ultrasound evaluation for nuchal translucency (NT). How do you counsel patients for or against the addition of NT screening if they are choosing integrated screening over other traditional screening?
That's a great question. When an obese patient has cell-free fetal DNA screening, the fetal fraction may be lower, such that there may be an increased likelihood that the screen will be uninformative. It is reasonable to explain this in general terms, but I would not recommend using a cut-off in practice until more data are available. In the study I mentioned, Ashoor and colleagues (Ultrasound Obstet Gynecol 2013; 41:26-32) estimated the proportion of pregnancies with low fetal fraction according to maternal weight, and they found that the proportion with low fetal fraction was 7% at a weight of 100 kg (220 lbs) and exceeded 50% at a weight of 160 kg (352 lbs 
